etonogestrel


( Last Updated : December 8, 2020)
Generic Name:
etonogestrel
Project Status:
Complete
Therapeutic Area:
Prevention of pregnancy
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Nexplanon
Project Line:
Reimbursement Review
Project Number:
SR0648-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details

Manufacturer Requested Reimbursement Criteria1:
Indicated for the prevention of pregnancy for up to 3 years
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated for the prevention of pregnancy for up to 3 years
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2
Call for patient input open May 06, 2020
Call for patient input closed June 25, 2020
Clarification:

- No patient input submission received
Submission received June 03, 2020
Clarification:

Submission was previously withdrawn and has been refiled by the sponsor

 
Submission accepted June 17, 2020
Review initiated June 18, 2020
Draft CADTH review report(s) provided to sponsor for comment July 31, 2020
Deadline for sponsors comments August 12, 2020
CADTH responses on draft review report(s) provided to sponsor September 03, 2020
Expert committee meeting (initial) September 16, 2020
Draft recommendation issued to sponsor September 28, 2020
End of embargo period October 13, 2020
Final recommendation issued to sponsor and drug plans October 20, 2020
Final recommendation posted October 22, 2020
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) November 03, 2020
CADTH review report(s) posted December 07, 2020

Files

Recommendation and Reasons

Clinical Report

Pharmacoeconomic Report